HQIP / Resources / Spotlight report on curative intent treatment of stage I–IIIa non-small-cell lung cancer
Spotlight report on curative intent treatment of stage I–IIIa non-small-cell lung cancer
Published: 09 Jul 2020
It is established that surgery and other treatments delivered with curative intent offer the best chance of long-term survival for patients with early-stage lung cancer. This spotlight audit focuses on patients with early-stage disease and good performance status and who did not receive surgery, to see if progress has been made since the first such spotlight report in 2017. In addition, the audit also investigates the complex management of patients with stage IIIa disease.
This report provides recommendations which multidisciplinary teams can implement for quality improvement with the aim of improving treatment rates as well as quality of treatment for patients with early-stage disease.
Key findings include:
62% (46% in 2015) of patients with early-stage disease who did not have surgery received radiotherapy, while 35% (46% in 2015) still received no specific anticancer treatment
15% declined surgery due to patient wishes (compared to 31% in 2015)
Of 212 patients with stage IIIa disease for whom complete staging data was obtained, only 35% underwent an endobronchial ultrasound (EBUS) and 10% had a magnetic resonance imaging (MRI) scan of the brain, as recommended by national guidelines